-The Indian Express Government privileges the private over the public, preferring trade to health In a dramatic development, US industry groups recently claimed the Indian government offered them a “private” assurance that compulsory licences will not be issued, save in emergencies and for non-commercial purposes. Needless to state, such an assurance flies in the face of the Patents Act and the public health safeguards enshrined in it. Illustratively, Section 84 mandates that...

-TheWire.in The government appears bent on decisively abandoning the earlier consensus of adherence to public health goals. In what is widely being hailed as an extraordinary victory for the multinational pharmaceutical industry over the Indian government, the US-India Business Council (USIBC), in its submission to the United States Trade Representative (USTR), reports that the Indian government has “privately assured” the industry that it would not use compulsory licences (CLs) for commercial purposes....

-The Indian Express The Central government’s move to fix cotton seed prices and trait fees sends wrong signals. 2015 will go down as a year that has seen all the rules of free trade being given the go-by when it comes to agriculture. The lead for it, significantly, has come from the Centre, whether in the form of not allowing exports of onion at below $ 700 a tonne or imposing stockholding...

-The Hindu India’s IPR regime, never in the background, has come under sharp focus recently for a variety of reasons. It is ten years since India amended the Indian Patents Act, 1970 to bring its laws in line with the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The most important of those amendments related to the introduction of product patents for 20 years, including for pharmaceutical products. Significant safeguards were...

-Economic and Political Weekly Ten years on, the progressive provisions of the amended Indian Patents Act are being watered down. Ten years have passed since the Indian Patents Act, 1970 was amended in 2005 to bring the country’s laws in line with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The most important of the 2005 amendments was the introduction of product patents for 20 years, including for pharmaceutical products,...